ABSTRACT
INTRODUCTION: Non-specific adsorption (NSA) of drugs to plastic or glass containers used in clinical use is well known, but methods for reducing NSA have been rarely reported. We assessed the NSA to various containers and then investigated methods to reduce NSA. METHODS: Probe drugs (methotrexate, warfarin, chloroquine, propranolol, verapamil, digoxin and paclitaxel) dissolved in water were incubated in conventional or low-adsorption containers for 4h at 4 degrees C and the NSA was determined by HPLC. They were also dissolved in aqueous methanol or acetonitrile and the NSA to a conventional polypropylene microplate was determined. Finally, tissue culture microplates were coated with silane coupling agents and the effects of the coatings were evaluated. RESULTS: Hydrophobic drugs (paclitaxel, verapamil and digoxin) were highly adsorbed to conventional plastic microplates, but in addition to hydrophobic drugs, positively charged drugs were well adsorbed to the tissue culture microplate. Low-adsorption microplates could reduce NSA below 15%, but positively charged or neutral hydrophobic drugs showed relatively higher adsorption. Acetonitrile showed stronger NSA inhibition than that of methanol, but the peak shapes of methotrexate and chloroquine were broadened and split. Among the silane coupling agents, GPTMS suppressed the NSA below 10%. Also, AATMS resembled the NSA pattern of GPTMS, but it increased the adsorption of methotrexate to 29%. DISCUSSION: On conventional plastic microplates, NSA is mainly driven by hydrophobic interactions, but on tissue culture microplates and low-adsorption microplates, in addition to hydrophobic interactions, ionic interactions play a role in the NSA. Therefore, to reduce the NSA to plastic containers, both hydrophobic and ionic interactions should be reduced using amphiphilic organic solvents or neutral and hydrophilic coatings.
Subject(s)
Biological Assay/standards , Drug Packaging , Pharmaceutical Preparations/metabolism , Plastics/pharmacokinetics , Adsorption , Biological Assay/methods , Drug Packaging/methods , Drug Stability , Hydrophobic and Hydrophilic Interactions , Silanes/pharmacokinetics , Surface PropertiesABSTRACT
INTRODUCTION: The Caco-2 permeability assay is widely used for lead optimization in drug discovery. A 3 to 5-day system using a 24-well plate and a 10 to 21-day system using a 96-well plate have been established. Here, we modified the assay system to provide a ready-to-use Caco-2 cell monolayer using a 96-well plate in just 4 days. METHODS AND RESULTS: In our system, collagen-coated inserts and the prolongation of the culture period after seeding leads to greater Caco-2 cell proliferation and sufficient contact-inhibition. The differentiation of Caco-2 cells was enhanced, when the contact-inhibited Caco-2 cells were exposed to the differentiation-inducing agent butyric acid. The permeability to nine well-known compounds showed a statistical correlation between our 4-day system using a 96-well plate and the conventional 21-day system using a 24-well plate. DISCUSSION: We conclude that our system is more useful for evaluating many compounds for lead optimization in drug discovery.
Subject(s)
Drug Discovery/methods , Butyric Acid/pharmacology , Caco-2 Cells , Cell Culture Techniques , Cell Differentiation/drug effects , Cell Membrane Permeability/drug effects , Cell Proliferation/drug effects , Cells, Cultured , Clinical Trials as Topic , Coated Materials, Biocompatible , Humans , Pharmaceutical Preparations/chemistry , Pharmaceutical Preparations/classification , Pharmaceutical Preparations/metabolism , Propranolol/pharmacology , Time Factors , Vinblastine/pharmacologyABSTRACT
Beraprost sodium (BPS), a chemically stable and orally active prostacyclin analogue used for the treatment of chronic occlusive disease and primary pulmonary hypertension, was investigated in terms of its drug-drug interaction mediated by cytochrome P450. In a metabolic enzyme characterization study using P450-expressing insect cell microsomes, beraprost (BP) was slightly metabolized in the presence of CYP2C8, but not metabolized by the other P450 isoforms (CYP1A2, [corrected] CYP2A6, CYP2B6, CYP2C9, CYP2C19, CYP2D6, CYP2E1, CYP3A4, and CYP4A11) at a concentration of 20 microM. These results suggest that none of the P450 isoforms is a major metabolic enzyme of BP. In a P450 induction study using human hepatocytes, BP did not induce any P450 isoform (CYP1A2, CYP2C9, CYP2C19, and CYP3A4) at concentrations of 1-100 microM. Furthermore, in a P450 inhibition study using human liver microsomes, BP did not inhibit any P450 isoform (CYP1A2, CYP2A6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, and CYP3A4) at concentrations of 0.05-1 microM. Therefore it is concluded that BP is not involved in drug-drug interaction mediated by P450 isoforms.
Subject(s)
Cytochrome P-450 Enzyme System , Epoprostenol/analogs & derivatives , Antihypertensive Agents/pharmacology , Arterial Occlusive Diseases , Chronic Disease , Cytochrome P-450 Enzyme System/metabolism , Drug Interactions , Epoprostenol/pharmacology , Humans , Hypertension, Pulmonary , In Vitro Techniques , Isoenzymes , Microsomes, Liver/enzymology , Platelet Aggregation Inhibitors/pharmacologyABSTRACT
Novel series of 3-amino-N-(4-aryl-1,1-dioxothian-4-yl)butanamides and 3-amino-N-(4-aryltetrahydropyran-4-yl)butanamides were synthesized and evaluated as dipeptidyl peptidase IV (DPP-IV) inhibitors. Derivatives incorporating the 6-substituted benzothiazole group showed highly potent DPP-IV inhibitory activity. Oral administration of (3R)-3-amino-4-(2,4,5-trifluorophenyl)-N-{4-[6-(2-methoxyethoxy)benzothiazol-2-yl]tetrahydropyran-4-yl}butanamide (12u) reduced blood glucose excursion in an oral glucose tolerance test.
Subject(s)
Benzothiazoles/chemical synthesis , Dipeptidyl Peptidase 4/chemistry , Dipeptidyl-Peptidase IV Inhibitors , Dipeptidyl-Peptidase IV Inhibitors/chemical synthesis , Enzyme Inhibitors/chemical synthesis , Pyrans/chemistry , Administration, Oral , Benzothiazoles/pharmacology , Blood Glucose/metabolism , Chemistry, Pharmaceutical/methods , Dipeptidyl-Peptidase IV Inhibitors/pharmacology , Drug Design , Enzyme Inhibitors/pharmacology , Gastric Emptying , Glucagon-Like Peptide 1/chemistry , Glucose Tolerance Test , Humans , Inhibitory Concentration 50 , Insulin-Secreting Cells/metabolism , Models, ChemicalABSTRACT
We disclose here a new structural class of low-molecular-weight inhibitors of NF-kappa B activation that were designed and synthesized by starting from quinazoline derivative 6a. Structure-activity relationship (SAR) studies based on 6a elucidated the structural requirements essential for the inhibitory activity toward NF-kappa B transcriptional activation, and led to the identification of the 6-amino-4-phenethylaminoquinazoline skeleton as the basic framework. In this series of compounds, 11q, containing the 4-phenoxyphenethyl moiety at the C(4)-position, showed strong inhibitory effects on both NF-kappa B transcriptional activation and TNF-alpha production. Furthermore, 11q exhibited an anti-inflammatory effect on carrageenin-induced paw edema in rats.
